

**dinoprostone 10mg vaginal delivery system
(Propess[®])**

(No. 283/06)

Ferring Pharmaceuticals Ltd

Product Update

9 June 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Dinoprostone 10mg vaginal delivery system (Propess[®]) is accepted for use in NHS Scotland for initiation of cervical ripening in patients at term (from 38th week of gestation)

This formulation replaces a product which released 5mg over 12 hours from a different 10 mg vaginal delivery system. The new pessary formulation can remain in place for up to 24 hours where necessary and the cost per pessary is unchanged.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 26 April 2006.

**Chairman,
Scottish Medicines Consortium**